



Human Motor Neuron Obtained from iPSCs as the Most Promising Tool to Define Pathomechanisms and Novel Therapies in ALS

Patrizia Bossolasco¹ and Vincenzo Silani^{1,2*}

¹Department of Neurology and Laboratory of Neuroscience, IRCCS Italian Auxological Institute, Milan, Italy

²Dino Ferrari Centre, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Editorial

Difficulty of translation from pre-clinical to clinical settings represents the main limitation in deciphering pathomechanisms of neurodegenerative diseases, and this is primarily due to the shortage of adequate pre-clinical models. This is especially true for Amyotrophic Lateral Sclerosis (ALS). Due to the absence of naturally occurring ALS in rodents, informative transgenic mice are the most frequently used animal models [1]. However, albeit they have been useful for studying some pathological mechanisms of the disease, none of them perfectly replicate the human ALS. Developmental and anatomical differences between mice and humans may explain the gap in translation. Several cellular models are also available such as neural cell lines [2-4]. However, as cell lines are mostly tumor-derived and have become immortalized, they may display significant biological differences from neuronal cells. Primary neuronal cultures would be therefore the most appropriate *in vitro* model, but the major problem is that mature neurons have limited proliferation capacity. As a matter of fact, Motor Neurons (MNs) have been isolated by immunomagnetic separation by our group [5], demonstrating some survival potential in serum-free media in defined biochemical conditions. The induced pluripotent stem cells (iPSCs) [6] represent a breakthrough in stem cell field. These cells may be generated using several delivery systems [7,8] and certainly present numerous advantages compared to other pre-clinical approaches, allowing the generation of patient specific models able to reproduce the disease phenotype. The iPSCs, unlike tumor cell lines, are primary cells but with an unlimited proliferation capability. They can be generated from any patient and can be differentiated into any cell type. In ALS, iPSCs-derived MNs may be obtained from both patients harboring genetic mutations linked to the disease (such as SOD1, TARDBP, FUS and C9ORF72) than from sporadic patients (the prevalent cases) without a disease family history. Beside their differentiation into MNS, iPSCs can generate other cell types that have been proved to have important implications in the disease, such as glial cells. Interactions between different neural cells can therefore be investigated *in vitro*. Albeit fibroblasts are most commonly used, several different starting cells have been reprogrammed and ideally, each dividing somatic cell may be used. Clinical, genetic and phenotypic heterogeneity of ALS may also lead to multiple and discordant responses with analogous treatment. Another important advantage using iPSCs, is the possibility to use cells from patients still alive, allowing to design a patient specific therapy [9].

OPEN ACCESS

*Correspondence:

Vincenzo Silani, Department of Neurology and Laboratory of Neuroscience, IRCCS Italian Auxological Institute, Dino Ferrari Centre, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy,

E-mail: vincenzo@silani.com

Received Date: 15 Dec 2017

Accepted Date: 26 Dec 2017

Published Date: 29 Dec 2017

Citation:

Bossolasco P, Silani V. Human Motor Neuron Obtained from iPSCs as the Most Promising Tool to Define Pathomechanisms and Novel Therapies in ALS. *Ann Transplant Res.* 2017; 1(2): 1008.

Copyright © 2017 Vincenzo Silani. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Thanks to the high versatility of iPSCs, the reprogramming of somatic cells from ALS patients and their differentiation to MNs may represent a major achievement in understanding the mechanism of ALS, identifying innovative therapeutical strategies. As a proof of principle, iPSC derived MNs have been also utilized to start a clinical trial in humans after FDA approval [10] if this approach is reproducible, other neurodegenerative diseases will definitely take great advantages from this innovative, unprecedented approach that may represent a paradigm shift for effective drug finding in ALS as in other neurodegenerative disorders.

References

1. Tan RH, Ke YD, Ittner LM, Halliday GM. ALS/FTLD: experimental models and reality. *Acta Neuropathol.* 2017;133(2):177-196.
2. Cashman NR, Durham HD, Blusztajn JK, Oda K, Tabira T, Shaw IT, et al. Neuroblastoma x spinal cord (NSC) hybrid cell lines resemble developing motor neurons. *Dev Dyn.* 1992;194(3):209-21.
3. Biedler JL, Helson L, Spengler BA. Morphology and growth, tumorigenicity, and cytogenetics of human

- neuroblastoma cells in continuous culture. *Cancer Res.* 1973;33(11):2643-52.
4. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. *J Gen Virol.* 1977;36(1):59-74.
 5. Silani V, Brioschi A, Braga M, Ciammola A, Zhou FC, Bonifati C, et al. Immuno magnetic isolation of human developing motor neurons. *Neuroreport.* 1998;9(6):1143-47.
 6. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell.* 2007;131:861-72.
 7. Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, Slukvin II, et al. Human induced pluripotent stem cells free of vector and transgene sequences. *Science.* 2009;324(5928):797-801.
 8. Miyoshi N, Ishii H, Nagano H, Haraguchi N, Dewi DL, Kano Y, et al. Reprogramming of mouse and human cells to pluripotency using mature micro RNAs. *Cell Stem Cell.* 2011;8(6):633-8.
 9. Avior Y, Sagi I, Benvenisty N. Pluripotent stem cells in disease modeling and drug discovery. *Nat Rev Mol Cell Biol.* 2016;17(3):170-82.
 10. Ludolph AC, Bendotti C, Blaugrund E, Chio A, Greensmith L, Loeffler JP, et al. Guidelines for preclinical animal research in ALS/MND: A consensus meeting. *Amyotroph Lateral Scler.* 2010;11(1-2):38-45.